

COVID-19 Assessment Centre Referral Form (For Paxlovid Therapy Assessment)

<input type="checkbox"/> Scarborough Health Network (Birchmount site)	3030 Birchmount Road Hours of operation: 8 am – 6:30 pm (7 days a week)	<input type="checkbox"/> Email referral form to: covidassessmentcentre@shn.ca
<input type="checkbox"/> Scarborough Health Network (Centenary site)	2867 Ellesmere Rd Hours of operation: Monday, 8 a.m. – 4 p.m. Friday, 11 a.m. – 7 p.m.	

NOTICE: Referrals to the SHN COVID-19 Assessment Clinic for Paxlovid therapy for COVID-19 patients with symptom onset 5 days or greater OR for long COVID-19 shall be respectfully declined due to patient ineligibility for Paxlovid therapy.

Patient Information	
Name: _____ Sex: _____ Date of Birth (DD/MM/YY): _____ Address: _____ Postal Code: _____ Phone Number: _____ HCN: _____	
Height (cm): _____ Weight (kg): _____ Allergies: <input type="checkbox"/> No known drug allergies	<p style="color: blue; font-size: small;">* REFERRING PHYSICIAN/REFEREE: PLEASE ATTACH A COPY OF THE PATIENT'S CURRENT MEDICATION LIST (prescription, non-prescription, over the counter and herbal medications WITH THE COMPLETED REFERRAL FORM) IF AVAILABLE *</p> <p style="font-size: small;">Brief medical history and relevant clinical concerns (<i>where applicable, documentation can be attached</i>):</p> <input type="checkbox"/> I confirm this information is provided in attached documentation (if not provided below)
<p>NOTE: For patients with mild COVID-19 with confirmed COVID-19. These products are available for use under an interim authorization (Interim Order) by Health Canada to prevent progression of mild to moderate COVID-19 in patients weighting at least 40 kg who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is indicated for patients 18 years and older.</p>	
CRITERIA FOR PAXLOVID THERAPY	
<p style="color: blue;">Patients <u>must</u> meet Criteria 1, 2, 3, and 4 and ALL fields must be <u>completed</u> to be eligible for Paxlovid treatment [nirmaltravir plus ritonavir]</p>	
1	<input type="checkbox"/> Patient is 18 years and older (Paxlovid is indicated for patients 18 years and older.)
2	<input type="checkbox"/> Patient is within 5 days of symptom onset (Treatment must be given within 5 days of symptom onset for Paxlovid) <input type="checkbox"/> Date of symptom onset: _____
3	<input type="checkbox"/> Patient has an active COVID-19 infection <input type="checkbox"/> Date of positive COVID-19 test: _____ AND <input type="checkbox"/> Type of COVID-19 test used <input type="checkbox"/> Rapid Antigen Test <input type="checkbox"/> PCR <input type="checkbox"/> Rapid Point of Care Molecular Test [ID Now]
4	<p>Patient must meet at least one criteria under A, B, C or D below:</p> <input type="checkbox"/> A) Immunocompromised or immunosuppressed individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection (regardless of vaccine status) defined as one of the following: <ul style="list-style-type: none"> <input type="checkbox"/> Active treatment for solid tumor and hematologic malignancies (including individuals with lymphoid malignancies who are being monitored without active treatment) (<i>Specify:</i> _____) <input type="checkbox"/> Receipt of solid-organ transplant and taking immunosuppressive therapy (<i>Specify:</i> _____) <input type="checkbox"/> Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)

COVID-19 Assessment Centre Referral Form (For Paxlovid Therapy Assessment)

	<input type="checkbox"/> Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome, common variable immunodeficiency, Good's syndrome, hyper IgE syndrome) (<i>Specify: _____</i>) <input type="checkbox"/> Advanced or untreated HIV infection <input type="checkbox"/> Active treatment with high-dose corticosteroids (i.e. equal or greater than 20 mg prednisone or equivalent per day when administered for equal or greater than 2 weeks) <input type="checkbox"/> Active treatment with alkylating agents, antimetabolites (including methotrexate), transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis factor (TNF) blockers or other biologic agents that are immunosuppressive or immunomodulatory (<i>Specify: _____</i>) <input type="checkbox"/> B) Age 70 years and older (irrespective of COVID-19 vaccination status) <input type="checkbox"/> C) Age 60 years and older with less than 3 doses of a COVID-19 vaccine <input type="checkbox"/> D) Age 18 years and older with less than 3 doses of a COVID-19 vaccine AND at least 1 of the following risk factors: <ul style="list-style-type: none"> • Diabetes Mellitus • Obesity (Body mass index equal or greater than 30 kg/m²) • Cardiovascular Disease (e.g. heart disease, congestive heart failure, hypertension) • Chronic Kidney Disease (eGFR 30 to less than 60 mL/min/1.73 m²) • Chronic Liver Disease (Child-Pugh class B) • Chronic Respiratory Disease (including cystic fibrosis) • Cerebral Palsy • Intellectual or Developmental Disability • Sickle Cell Disease • Pregnancy
--	--

Prescriber/Referee Attestation (Must be checked to be eligible for treatment)

<input type="checkbox"/> I affirm that my patient meets above criteria for use	
Prescriber/Referee Name (print): _____	Direct Contact Number (not office line): _____
Prescriber/Referee Signature: _____	Date/Time: _____
CPSO# (if applicable): _____	
Referral Physician's Billing # (if applicable): _____	
<input type="checkbox"/> RN/RPN (if applicable)	